The Main Events in the History of Diabetes Mellitus
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Therapeutic Medications Against Diabetes: What We Have and What We Expect
Advanced Drug Delivery Reviews 139 (2019) 3–15 Contents lists available at ScienceDirect Advanced Drug Delivery Reviews journal homepage: www.elsevier.com/locate/addr Therapeutic medications against diabetes: What we have and what we expect Cheng Hu a,b, Weiping Jia a,⁎ a Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Key Clinical Center for Metabolic Diseases, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai 200233, People's Republic of China b Shanghai Jiao Tong University Affiliated Sixth People's Hospital South Campus, 6600 Nanfeng Road, Shanghai 200433, People's Republic of China article info abstract Article history: Diabetes has become one of the largest global health and economic burdens, with its increased prevalence and Received 28 June 2018 high complication ratio. Stable and satisfactory blood glucose control are vital to reduce diabetes-related compli- Received in revised form 1 September 2018 cations. Therefore, continuous attempts have been made in antidiabetic drugs, treatment routes, and traditional Accepted 27 November 2018 Chinese medicine to achieve better disease control. New antidiabetic drugs and appropriate combinations of Available online 5 December 2018 these drugs have increased diabetes control significantly. Besides, novel treatment routes including oral antidia- betic peptide delivery, nanocarrier delivery system, implantable drug delivery system are also pivotal for diabetes Keywords: fi Diabetes control, with its greater ef ciency, increased bioavailability, decreased toxicity and reduced dosing frequency. Treatment Among these new routes, nanotechnology, artificial pancreas and islet cell implantation have shown great poten- Drug delivery tial in diabetes therapy. Traditional Chinese medicine also offer new options for diabetes treatment. -
July 2020 Strategies for Emerging Infectious Diseases
THE AMERICAN WWW.CAYMANCHEM.COM ASSOCIATION OF IMMUNOLOGISTS AT ISSUE NEW THE DOWNLOAD Virus Life Cycle Infographic Infographic Cycle Life Virus JULY 2020 Resources for Your Research Your for Resources Informative Articles Informative CAYMAN CURRENTS: CAYMAN IN THIS ISSUE OF THE THE OF ISSUE THIS IN DISEASES INFECTIOUS EMERGING AAI Looks Back: How Honolulu’s Chinatown FOR STRATEGIES "Went Up in Smoke" A history of the first plague outbreak in Hawai’i, page 30 ANTIVIRAL 28 No. Permit CAYMAN CURRENTS PA Gettysburg, PAID 20852 20852 20852 20852 MD MD MD MD Rockville, Rockville, Rockville, Rockville, 650, 650, 650, 650, Suite Suite Suite Suite Pike, Pike, Pike, Pike, Rockville Rockville Rockville Rockville 1451 1451 1451 1451 Postage U.S. Non-Proft Org. Non-Proft IMMUNOLOGISTS IMMUNOLOGISTS IMMUNOLOGISTS IMMUNOLOGISTS OF OF OF OF ASSOCIATION ASSOCIATION ASSOCIATION ASSOCIATION AMERICAN AMERICAN AMERICAN AMERICAN THE THE THE THE 2020 advanced Course in Immunology Now Virtual! I July 26–31, 2020 IN THIS ISSUE Director: Wayne M. Yokoyama, M.D. Washington University School of Medicine in St. Louis x4 Executive Offce The American Association Don’t miss the premier course in immunology for research scientists! of Immunologists x8 Public Affairs This intensive course is directed toward advanced trainees and scientists who wish to expand or update 1451 Rockville Pike, Suite 650 their understanding of the feld. Leading experts will present recent advances in the biology of the Rockville, MD 20852 20 Members in the News immune system and address its role in health and disease. This is not an introductory course; Tel: 301-634-7178 attendees will need to have a frm understanding of the principles of immunology. -
A History of Diabetes NYSNA Continuing Education the New
A History of Diabetes NYSNA Continuing Education The New York State Nurses Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This course has been awarded 1.2 contact hours. All American Nurses Credentialing Center (ANCC) accredited organizations' contact hours are recognized by all other ANCC accredited organizations. Most states with mandatory continuing education requirements recognize the ANCC accreditation/approval system. Questions about the acceptance of ANCC contact hours to meet mandatory regulations should be directed to the Professional licensing board within that state. NYSNA has been granted provider status by the Florida State Board of Nursing as a provider of continuing education in nursing (Provider number 50-1437). A History of Diabetes 1 © 2004 NYSNA, all rights reserved. Material may not be reproduced without written permission. How to Take This Course Please take a look at the steps below; these will help you to progress through the course material, complete the course examination and receive your certificate of completion. 1. REVIEW THE OBJECTIVES The objectives provide an overview of the entire course and identify what information will be focused on. Objectives are stated in terms of what you, the learner, will know or be able to do upon successful completion of the course. They let you know what you should expect to learn by taking a particular course and can help focus your study. 2. STUDY EACH SECTION IN ORDER Keep your learning "programmed" by reviewing the materials in order. This will help you understand the sections that follow. -
Postoperative Tight Glycemic Control
Wang et al. BMC Endocrine Disorders (2018) 18:42 https://doi.org/10.1186/s12902-018-0268-9 RESEARCHARTICLE Open Access Postoperative tight glycemic control significantly reduces postoperative infection rates in patients undergoing surgery: a meta-analysis Yuan-yuan Wang1, Shuang-fei Hu2, Hui-min Ying1, Long Chen2, Hui-li Li1, Fang Tian1 and Zhen-feng Zhou2* Abstract Background: The benefit results of postoperative tight glycemic control (TGC) were controversial and there was a lack of well-powered studies that support current guideline recommendations. Methods: The EMBASE, MEDLINE, and the Cochrane Library databases were searched utilizing the key words “Blood Glucose”, “insulin” and “Postoperative Period” to retrieve all randomized controlled trials evaluating the benefits of postoperative TGC as compared to conventional glycemic control (CGC) in patients undergoing surgery. Results: Fifteen studies involving 5053 patients were identified. As compared to CGC group, there were lower risks of total postoperative infection (9.4% vs. 15.8%; RR 0.586, 95% CI 0.504 to 0.680, p < 0.001) and wound infection (4. 6% vs. 7.2%; RR 0.620, 95% CI 0.422 to 0.910, p = 0.015) in TGC group. TGC also showed a lower risk of postoperative short-term mortality (3.8% vs. 5.4%; RR 0.692, 95% CI 0.527 to 0.909, p = 0.008), but sensitivity analyses showed that the result was mainly influenced by one study. The patients in the TGC group experienced a significant higher rate of postoperative hypoglycemia (22.3% vs. 11.0%; RR 3.145, 95% CI 1.928 to 5.131, p < 0.001) and severe hypoglycemia (2.8% vs. -
Year 11 GCSE History Paper 1 – Medicine Information Booklet
Paper 1 Medicine Key topics 1 and 2 (1250-1500, 1500-1700) Year 11 GCSE History Paper 1 – Medicine Information booklet Medieval Renaissance 1250-1500 1500-1750 Enlightenment Modern 1900-present 1700-1900 Case study: WW1 1 Paper 1 Medicine Key topics 1 and 2 (1250-1500, 1500-1700) Key topic 1.1 – Causes of disease 1250-1500 At this time there were four main ideas to explain why someone might become ill. Religious reasons - The Church was very powerful at this time. People would attend church 2/3 times a week and nuns and monks would care for people if they became ill. The Church told people that the Devil could infect people with disease and the only way to get better was to pray to God. The Church also told people that God could give you a disease to test your faith in him or sometimes send a great plague to punish people for their sins. People had so much belief in the Church no-one questioned the power of the Church and many people had believed this explanation of illness for over 1,000 years. Astrology -After so many people in Britain died during the Black Death (1348-49) people began to look for new ways to explain why they became sick. At this time doctors were called physicians. They would check someone’s urine and judge if you were ill based on its colour. They also believed they could work out why disease you had by looking at where the planets were when you were born. -
Early History of Infectious Disease
© Jones and Bartlett Publishers. NOT FOR SALE OR DISTRIBUTION CHAPTER ONE EARLY HISTORY OF INFECTIOUS 1 DISEASE Kenrad E. Nelson, Carolyn F. Williams Epidemics of infectious diseases have been documented throughout history. In ancient Greece and Egypt accounts describe epidemics of smallpox, leprosy, tuberculosis, meningococcal infections, and diphtheria.1 The morbidity and mortality of infectious diseases profoundly shaped politics, commerce, and culture. In epidemics, none were spared. Smallpox likely disfigured and killed Ramses V in 1157 BCE, although his mummy has a significant head wound as well.2 At times political upheavals exasperated the spread of disease. The Spartan wars caused massive dislocation of Greeks into Athens triggering the Athens epidemic of 430–427 BCE that killed up to one half of the population of ancient Athens.3 Thucydides’ vivid descriptions of this epidemic make clear its political and cultural impact, as well as the clinical details of the epidemic.4 Several modern epidemiologists have hypothesized on the causative agent. Langmuir et al.,5 favor a combined influenza and toxin-producing staphylococcus epidemic, while Morrens and Chu suggest Rift Valley Fever.6 A third researcher, Holladay believes the agent no longer exists.7 From the earliest times, man has sought to understand the natural forces and risk factors affecting the patterns of illness and death in society. These theories have evolved as our understanding of the natural world has advanced, sometimes slowly, sometimes, when there are profound break- throughs, with incredible speed. Remarkably, advances in knowledge and changes in theory have not always proceeded in synchrony. Although wrong theories or knowledge have hindered advances in understanding, there are also examples of great creativity when scientists have successfully pursued their theories beyond the knowledge of the time. -
History and Scope of Microbiology the Story of Invisible Organisms
A study material for M.Sc. Biochemistry (Semester: IV) Students on the topic (EC-1; Unit I) History and Scope of Microbiology The story of invisible organisms Dr. Reena Mohanka Professor & Head Department of Biochemistry Patna University Mob. No.:- +91-9334088879 E. Mail: [email protected] MICROBIOLOGY 1. WHAT IS A MICROBIOLOGY? Micro means very small and biology is the study of living things, so microbiology is the study of very small living things normally too small that are usually unable to be viewed with the naked eye. Need a microscope to see them Virus - 10 →1000 nanometers Bacteria - 0.1 → 5 micrometers (Human eye ) can see 0.1 mm to 1 mm Microbiology has become an umbrella term that encompasses many sub disciplines or fields of study. These include: - Bacteriology: The study of bacteria - Mycology: Fungi - Protozoology: Protozoa - Phycology: Algae - Parasitology: Parasites - Virology: Viruses WHAT IS THE NEED TO STUDY MICROBIOLOGY • Genetic engineering • Recycling sewage • Bioremediation: use microbes to remove toxins (oil spills) • Use of microbes to control crop pests • Maintain balance of environment (microbial ecology) • Basis of food chain • Nitrogen fixation • Manufacture of food and drink • Photosynthesis: Microbes are involved in photosynthesis and accounts for >50% of earth’s oxygen History of Microbiology Anton van Leeuwenhoek (1632-1723) (Dutch Scientist) • The credit of discovery of microbial world goes to Anton van Leeuwenhoek. He made careful observations of microscopic organisms, which he called animalcules (1670s). • Antoni van Leeuwenhoek described live microorganisms that he observed in teeth scrapings and rain water. • Major contributions to the development of microbiology was the invention of the microscope (50-300X magnification) by Anton von Leuwenhoek and the implementation of the scientific method. -
Intensive Insulin Therapy for Tight Glycemic Control Research Therapy Monitoring Nursing
Proceedings from The Seventh Conference The CareFusion Center for Safety and Clinical Excellence June 7-8, 2007, San Diego, CA Philip J. Schneider, MS, FASHP, Editor Intensive Insulin Therapy for Tight Glycemic Control Research Therapy Monitoring Nursing Conference Report Published by The CareFusion Center for Safety and Clinical Excellence www.cardinalhealth.com/clinicalcenter International Conference on Intensive Insulin Therapy for Tight Glycemic Control The seventh invitational conference at the CareFusion Center for Safety and Clinical Excellence in San Diego, held June 7-8, 2007, brought together a distinguished faculty from clinical practice, academia, and organizations. Judith Jacobi, PharmD, FCCM, FCCP, BCPS, Critical Care Pharmacist, Methodist Hospital/Clarian Health, Indianapolis, IN and Timothy S. Bailey, MD, FACE, CPI, Advanced Metabolic Care and Research, Escondido, CA chaired the conference. Internationally recognized experts on research, current issues and opportunities in the use of intensive insulin therapy for tight glycemic control (TGC IIT) presented. This conference report summarizes the information presented on TGC IIT with regard to research findings, safety concerns, emerging practices, monitoring, and nursing issues as researchers and clinicians seek to optimize insulin therapy to help maintain normoglycemia in critically ill patients. The proceedings were edited by Philip J. Schneider, MS, FASHP, Clinical Professor and Director, Latiolais Leadership Program, College of Pharmacy, The Ohio State University, Columbus, -
Pharmacist Glycemic Control Team Associated with Improved
At a Glance Original Research Practical Implications p e128 Author Information p e134 Full text and PDF www.ajmc.com Web exclusive Pharmacist Glycemic Control Team Associated With Improved Perioperative Glycemic and Utilization Outcomes David M. Mosen, PhD, MPH; Karen S. Mularski, MD; Richard A. Mularski, MD, MSHS, MCR; Ariel K. Hill, AB; and Elizabeth Shuster, MS atients with diabetes and stress hyperglycemia are frequently hospitalized for surgical procedures,1 and ABSTRACT recent estimates indicate that 30% to 50% of US inpa- Objectives: Perioperative hyperglycemia is a risk factor for P 1,2 tients have diabetes and/or hyperglycemia. Multiple studies increased surgical morbidity and mortality. Pharmacy-led manage- have documented the risks of perioperative hyperglycemia, ment teams may improve glycemic control and postoperative out- including poor surgical outcomes and higher readmission comes. We sought to determine whether a pharmacist-led glycemic control team is associated with improved glycemic control and rates.1-4 However, improved glycemic control leads to reduc- reduced postdischarge utilization and medical costs. tions in hospital complications, length of stay, and mortality.1,5-7 Study Design: Retrospective, observational study. Multiple professional societies, agencies, and task forces have issued guidelines recommending methods to achieve Methods: We assessed patient-level outcomes during a 12-month pre-intervention period and compared them at years 1 and 2 post safe and effective glycemic control in hospitalized patients.8-12 implementation at a tertiary care multi-specialty medical center. Although the optimal target glucose range for hospitalized The patients were noncritically ill postoperative surgical patients patients continues to evolve based on results of recent clini- followed 72 hours post surgery (days 1-3). -
The Discovery of Insulin
Diabetes Frederick Banting and Charles Best purified the hormone • 1996: The introduction of insulin analogues with higher The Discovery of Insulin: The Ultimate Key insulin from bovine pancreases and administered it to and improved Absorption, Distribution, Metabolism and a first patient in 1922. The result was an elimination of Excretion (ADME). glycosuria (glucose in the urine) and a 77% drop of • 2005: FDA approves a new drug for type 2 Diabetes to Uncovering the Secret of Diabetes glycaemia (glucose in the blood) for the patient. derived from the Gila monster. Exendin4, found in the venom of the lizard triggers one of the insulin- releasing By the fall of 1923, 25000 patients were treated with pathways. Dr. Alice Gerges Geagea insulin injections in Canada and the United States. Banting • 2008: Suzanna M. de la Monte proposes the term “ type 3 received a Noble prize for this breakthrough and World diabetes ” to describe insulin resistance in the brain. PharmD, PhD, MSc Public Health Diabetes Day is now being celebrated worldwide on • 2013: The University of Cambridge trials an artificial November 14 which coincides with Banting’sbirthday. pancreas which combines the technology of an insulin It is well established that diabetes mellitus is a chronic pump with a continuous glucose monitor. disease caused by inherited and/or acquired deficiency in Other important landmark discoveries can be cited such • 2015: Dr Edward Damiano introduces the iLet , a bionic production of insulin by the pancreas or the ineffectiveness as: pancreas that delivers both insulin and glucagon every of the insulin produced. Such a deficiency results in • 1922: Development of Metformin which is now, among five minutes. -
2016 Standards of Medical Care in Diabetes
THE JOURNAL OF CLINICAL AND APPLIED RESEARCH AND EDUCATION VOLUME 39 | SUPPLEMENT 1 WWW.DIABETES.ORG/DIABETESCARE JANUARY 2016 PLE M E P N U T S 1 AMERICAN DIABETES ASSOCIATION STANDARDS OF MEDICAL CARE IN DIABETES—2016 ISSN 0149-5992 American Diabetes Association Standards of Medical Care in Diabetesd2016 January 2016 Volume 39, Supplement 1 [T]he simple word Care may suffice to express [the journal’s] philosophical mission. The new journal is designed to promote better patient care by serving the expanded needs of all health professionals committed to the care of patients with diabetes. As such, the American Diabetes Association views Diabetes Care as a reaffirmation of Francis Weld Peabody’s contention that “the secret of the care of the patient is in caring for the patient.” —Norbert Freinkel, Diabetes Care, January-February 1978 EDITOR IN CHIEF William T. Cefalu, MD ASSOCIATE EDITORS EDITORIAL BOARD George Bakris, MD Nicola Abate, MD Rita Rastogi Kalyani, MD, MHS, FACP Lawrence Blonde, MD, FACP Silva Arslanian, MD Rory J. McCrimmon, MBChB, MD, FRCP Andrew J.M. Boulton, MD Angelo Avogaro, MD, PhD Harold David McIntyre, MD, FRACP David D’Alessio, MD Ananda Basu, MD, FRCP Gianluca Perseghin, MD Sherita Hill Golden, MD, MHS, FAHA John B. Buse, MD, PhD Anne L. Peters, MD Mary de Groot, PhD Sonia Caprio, MD Jonathan Q. Purnell, MD Eddie L. Greene, MD Robert Chilton, DO Peter Reaven, MD Frank B. Hu, MD, MPH, PhD Kenneth Cusi, MD, FACP, FACE Helena Wachslicht Rodbard, MD Derek LeRoith, MD, PhD Paresh Dandona, MD, PhD David J. Schneider, MD Robert G. -
Health Plan Insights
Health Plan Insights August 2020 Updates from July 2020 800.361.4542 | envisionrx.com Confidential - Document has confidential information and may not be copied, published or distributed, in whole or in part, in any form or medium, without EnvisionRxOptions’ prior written consent. Recent FDA Approvals New Medications TRADE NAME DOSAGE FORM APPROVAL MANUFACTURER INDICATION(S) (generic name) STRENGTH DATE ByfavoTM Acacia Pharma, Injection, for IV use For the induction and maintenance of procedural July 2, 2020 (remimazolam) Inc. Eq 20 mg/vial sedation in adults undergoing procedures lasting 30 minutes or less. RukobiaTM ViiV Healthcare Extended-Release For use in combination with other antiretroviral(s), July 2, 2020 (fostemsavir) Tablets, for the treatment of HIV-1 infection in heavily 600 mg treatment-experienced adults with multidrug- resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. QwoTM Endo Aesthetics Injection for SQ For the treatment of moderate to severe cellulite July 6, 2020 (collagenase LLC use, in the buttocks of adult women. clostridium 0.92 mg and 1.84 histolyticum-aaes) mg Hulio® Mylan Injection for SQ For the treatment of Rheumatoid Arthritis, July 6, 2020 (adalimumab-fkjp) Pharmaceuticals use, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Inc. 40 mg/0.8 mL and Ankylosing Spondylitis, Adult Crohn’s Disease, 20 mg/0.4 mL Ulcerative Colitis, and Plaque Psoriasis. Inqovi® Otsuka Tablets, For the treatment of adult patients with July 7, 2020 (decitabine and Pharmaceutical 35 mg/100 mg myelodysplastic syndromes (MDS), including cedazuridine) Company, Ltd. previously treated and untreated, de novo and secondary MDS with the following FrenchAmerican-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.